Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Status:
Terminated
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of genetically modified T cells
in treating patients with stage III-IV non-small cell lung cancer (NSCLC) or mesothelioma.
Many types of cancer cells, including NSCLC and mesothelioma, but not most normal cells, have
a protein called Wilms tumor (WT)1 on their surfaces. This study takes a type of immune cell
from patients, called T cells, and modifies their genes in the laboratory so that they are
programmed to find cells with WT1 and kill them. The T cells are then given back to the
patient. Cyclophosphamide and aldesleukin may also stimulate the immune system to attack
cancer cells. Giving cyclophosphamide and aldesleukin with laboratory-treated T cells may
help the body build an immune response to kill tumor cells.